ASCO is assembling a cohort of its members who are willing to participate in survey-based research projects of ASCO members for non-commercial purposes. The immense knowledge and experience of ASCO’s membership can help to accelerate the development of new insights and findings that may help to improve care and care delivery.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
The Center for Medicare & Medicaid Services (CMS) has released performance feedback for Merit-based Incentive Payment System (MIPS) clinicians who participated the 2017 performance year. Individual clinicians, groups, and eligible clinicians in certain Alternative Payment Models (APMs) can access a comprehensive overview of their MIPS final score, performance category details, and 2019 MIPS payment adjustment on the Quality Payment Program (QPP) website.
The Centers for Medicare & Medicaid Services (CMS) and its contractor, Acumen LLC, are field testing 13 cost measures before consideration of their potential use in the cost performance category of the Merit-based Incentive Payment System (MIPS) under the Quality Payment Program in 2020 or beyond.
On September 28, 2018, the Food and Drug Administration approved cemiplimab-rwlc (LIBTAYO®, Regeneron Pharmaceuticals Inc.) for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
The ASCO Research Community Forum (RCF) 2018 Annual Meeting brought together 159 physician investigators and research staff from 34 states across the country—its largest meeting to-date—to discuss contemporary challenges and develop creative solutions in conducting and managing clinical trials. The meeting, held annually at ASCO's headquarters in the Washington DC Metro area, spanned two days from September 23-24, with a theme of Innovative Solutions. Best Practices. Excellence in Cancer Research.
In a comment letter from ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, to the Food and Drug Administration (FDA) Commissioner Scott Gottlieb, the society expressed appreciation for FDA’s efforts to gather stakeholder perspectives on enhancing access to biologic cancer therapies and ensuring greater availability of biosimilars, while retaining a balance between innovation and competition.
On September 27, 2018, the Food and Drug Administration approved dacomitinib tablets (VIZIMPRO, Pfizer Pharmaceutical Company) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
More than 100 ASCO volunteers from across the country came to Capitol Hill on September 25-26 for the 2018 ASCO Advocacy Summit, where they urged Congress to act on major policy priorities to support cancer research and ensure access to high-quality care for the millions of people in the United States with cancer.
ASCO applauds Congress for passing a $2 billion increase in funding for the National Institutes of Health (NIH), which will bring NIH's budget to a total of $39.1 billion and the National Cancer Institute's to a total of $6.147 billion.
In a comment letter to the Centers for Medicare & Medicaid Services (CMS) ASCO expressed significant concerns that provisions in the 2019 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule would undermine Medicare beneficiary access to cancer care due to reimbursement cuts based on site-of-service that fail to address systemic payment deficiencies for cancer care services under Medicare. ASCO urges CMS to forego implementing any additional utilization management strategies and instead enhance patient access to cancer care by facilitating participation in Advanced Alternative Payment Models (APMs) that use oncology clinical pathways to promote high-quality cancer care.
The American Society of Clinical Oncology presented Representative Kevin Yoder (KS-03) with the 2018 Congressional Leadership Award today. Each year, ASCO presents this Award to a Member of Congress who has continuously supported legislation that promotes an improved practice environment for the oncology community and improves the quality of care for cancer patients
The American Society of Clinical Oncology (ASCO) presented its 2017 Advocate of the Year Award to Ray D. Page, DO, PhD, FACOI, for his exceptional advocacy efforts on behalf of individuals living with cancer and their cancer care teams. As a member of the Government Relations Committee and in other roles, Dr. Page has provided distinguished leadership in the society’s policy and advocacy efforts.
ASCO is now holding Quality Training Program seminars outside of the U.S. for practices interested in participating.
On September 24, 2018, the Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In addition, duvelisib received accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Last week, the Food and Drug Administration (FDA) announced a series of critical enforcement actions related to the sale and marketing of e-cigarettes to children and young adults. With the use of e-cigarettes among youth growing at an alarming rate in recent years, the agency has taken record actions to address this challenge and protect youth from the dangers of tobacco products through its Youth Tobacco Prevention Plan.